Pembrolizumab/Vibostolimab

BIOLOGICAL6 trials

Conditions

Carcinoma, Non-Small-Cell LungColorectal CancerLung NeoplasmsMelanomaMetastatic Non-Small Cell Lung CancerNeoplasm MetastasisNon-Small-Cell Lung Carcinoma

Phase 1

A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)

WithdrawnNCT06395090

Merck Sharp & Dohme LLCNeoplasm Metastasis

Start: 2025-01-15End: 2029-06-30Updated: 2025-04-08

Phase 2

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)

Active, not recruitingNCT04895722

Merck Sharp & Dohme LLCColorectal Cancer

Start: 2021-06-25End: 2026-08-13Updated: 2026-03-30

Phase 3

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

CompletedNCT04738487

Merck Sharp & Dohme LLCLung Neoplasms, Non-Small-Cell Lung Carcinoma

Start: 2021-04-07End: 2026-01-27Updated: 2026-02-20

Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

CompletedNCT05226598

Merck Sharp & Dohme LLCMetastatic Non-Small Cell Lung Cancer

Start: 2022-03-24End: 2026-01-09Updated: 2026-02-05

Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

Active, not recruitingNCT05298423

Merck Sharp & Dohme LLCCarcinoma, Non-Small-Cell Lung

Start: 2022-05-03End: 2026-08-19Updated: 2025-08-01

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

CompletedNCT05665595

Merck Sharp & Dohme LLCMelanoma

Start: 2023-01-19End: 2025-09-26Updated: 2025-10-15

Journal of Clinical Oncology2026-01-10

Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC.

2024-10-19

KEYSTEP-008: Phase II Trial of Pembrolizumab-Based Combination in MSI-H/dMMR Metastatic Colorectal Cancer

Future Oncology2023-09-1312 citations

KEYVIBE-010: Adjuvant coformulated vibostolimab with pembrolizumab versus adjuvant pembrolizumab in patients with high-risk stage II-IV melanoma.

Journal of Clinical Oncology2023-06-0111 citations

Abstract CT561: KeyVibe-003: Randomized, double-blind, phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC

Cancer Research2022-06-152 citations

A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.

Journal of Clinical Oncology2022-06-015 citations

Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) stage IV colorectal cancer (CRC).

Journal of Clinical Oncology2022-06-012 citations

459 Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1–positive metastatic NSCLC

Regular and Young Investigator Award Abstracts2021-11-01

Pembrolizumab/Vibostolimab

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers